Johnson & Johnson’s experimental Covid-19 vaccine phase 1/2 trial findings have provided some encouragement.
Reports
the Wall Street Journal:
Now for some caveats. These are from a small early-stage trial. They are interim, posted on online preprint server medRxiv. The report is not yet peer-reviewed, not yet published in medical journals.
Reports
the Wall Street Journal:
Now for some caveats. These are from a small early-stage trial. They are interim, posted on online preprint server medRxiv. The report is not yet peer-reviewed, not yet published in medical journals.